- Home
- ANAB vs ELVN Comparison
ANAB vs ELVN Comparison
Compare ANAB & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ELVN
- Stock Information
- Founded
- ANAB 2005
- ELVN 2016
- Country
- ANAB United States
- ELVN United States
- Employees
- ANAB N/A
- ELVN N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- ELVN Health Care
- Exchange
- ANAB Nasdaq
- ELVN Nasdaq
- Market Cap
- ANAB 1.0B
- ELVN 1.2B
- IPO Year
- ANAB 2017
- ELVN 2020
- Fundamental
- Price
- ANAB $38.47
- ELVN $18.30
- Analyst Decision
- ANAB Buy
- ELVN Strong Buy
- Analyst Count
- ANAB 12
- ELVN 5
- Target Price
- ANAB $63.30
- ELVN $41.20
- AVG Volume (30 Days)
- ANAB 364.4K
- ELVN 596.7K
- Earning Date
- ANAB 11-04-2025
- ELVN 11-07-2025
- Dividend Yield
- ANAB N/A
- ELVN N/A
- EPS Growth
- ANAB N/A
- ELVN N/A
- EPS
- ANAB N/A
- ELVN N/A
- Revenue
- ANAB $169,467,000.00
- ELVN N/A
- Revenue This Year
- ANAB $37.52
- ELVN N/A
- Revenue Next Year
- ANAB N/A
- ELVN $20.05
- P/E Ratio
- ANAB N/A
- ELVN N/A
- Revenue Growth
- ANAB 196.42
- ELVN N/A
- 52 Week Low
- ANAB $12.21
- ELVN $13.30
- 52 Week High
- ANAB $40.96
- ELVN $29.79
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- ELVN 37.71
- Support Level
- ANAB $34.22
- ELVN $17.77
- Resistance Level
- ANAB $37.08
- ELVN $24.64
- Average True Range (ATR)
- ANAB 2.03
- ELVN 1.42
- MACD
- ANAB -0.18
- ELVN -0.43
- Stochastic Oscillator
- ANAB 68.07
- ELVN 6.11
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.